Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-05
2006-12-05
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007210, C435S007200, C435S007230, C530S350000, C530S387100, C530S387700, C436S086000, C436S087000, C436S164000, C436S536000
Reexamination Certificate
active
07144704
ABSTRACT:
This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.
REFERENCES:
patent: 4837306 (1989-06-01), Ling et al.
patent: 4918163 (1990-04-01), Young et al.
patent: 4925787 (1990-05-01), Tanihara et al.
patent: 5057598 (1991-10-01), Pollack et al.
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5130127 (1992-07-01), Herlyn
patent: 5132405 (1992-07-01), Huston et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5204095 (1993-04-01), Goodall et al.
patent: 5206352 (1993-04-01), Roninson et al.
patent: 5215913 (1993-06-01), Posner
patent: 5434075 (1995-07-01), Mechetner et al.
patent: 5464753 (1995-11-01), Chaudhary et al.
patent: WO 93 19094 (1993-09-01), None
Akiyama et al., “Most Drugs that Reverse Multidrug Resistance Also Inhibit Photoaffinity Labeling of P-Glycoprotein by a vinblastine Analog”,Molec. Pharm.33:144(1988).
Arcesi et al., “Monoclonal Antibody to an External Epitope of the Human mdr1 P-Glycoprotein1”Cancer Res.53:310-317(1993).
Ball et al., “Correlation of CD34 and Multi-Drug Resistance P170 with FAB and Cytogenetics but not prognosis in Acute Myeloid Leukemia”, 1990Blood76(10, Suppl 1):252a.
Barth et al., “Interferon γ and Tumor Necrosis Factor Have a Role in Tumor Regressions Mediated by Murine CD8+ Tumor-infiltrating Lymphocytes”, 1991,J. Exp. Med.173:647-658.
Beck et al., “Do Anti-P-Glycoprotein Antibodies Have a Future in the Circumvention of Multidrug Resistance”,J. Natl. Cancer Inst.83:1364-1366, Oct. 2, 1991.
Chaudhary et al., “Expression and Activity of P-Glycoprotein, a Multidrug Efflux Pump, in Human Hematopoietic Stem Cells”Cell66:85 (1991).
Chaudhary et al., “Expression and Activity of the Multidrug Resistance P-Glycoprotein in Human Peripheral Blood Lymphocytes”,Blood80:2735 (1992).
Chen et al., “Internal Duplication and Homology with Bacterial Transport Proteins in the mdr1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells”Cell47:381 (1986).
Choi et al., An Altered Pattern of Cross-Resistance Human Cells Results from Spontaneous Mutations in the mdr 1 (P-Glycoprotein) GeneCell53:519-529 (1988).
Choi et al., “Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-Glycoprotein density in the plasma membrane and is not affected by cytotoxic selection”,Proc. Natl. Acad. Sci. USA88:7386-7390 (1991).
Co & Queen, “Humanized antibodies for therapy”, 1991Nature351:501-502.
Coon et al., “Multidrug Resistance Activity in Human Lymphocytes”Human Immunol.32:134 (1991).
Cordon-Cardo et al. “Expression of the Multidrug Resistance Gene Product (P-Glycoprotein) in Human Normal and Tumor Tissues”,J. Histochem. Cytochem38:1277 (1990).
Cornwell et al., “Increased Vinblastine Binding to Membrane Vesicles from Multidrug-resistant KB Cells”J. Bio. Chem.261:7921 (1986).
Dillman et al., “Monoclonal Antibodies for Treating Cancer”Annals. Of Internal Med.111(7):592 (1989).
Drach et al., “Subpopulations of Normal Peripheral Blood and Bone Marrow Cells Express a Functional Multidrug Resistant Phenotype”Blood80:2729 (1992).
Efferth et al., “Reciprocal Correlation Betwwen Expression of P-Glycoptotein and Accumulation of Rhodamine 123 in Human Tumors” 1989,Anti. Cancer Research9:1633-1638.
Endicott & Ling, The Biochemistry of P-Glycoprotein-Mediated Multidrug ResistanceAnnu. Rev. Biochem,58:137 (1989).
Ford et al., “Pharmacology of Drugs that Alter Multidrug Resistance in Cancer”Pharm. Rev.42:155 (1990).
Georges et al. “Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies”PNAS(USA) 87:152-156 (1990).
Gillies et al., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities”Human Antibod. Hybridons1(1):47 (1990).
Gillis, “T-Cell-Derived Lymphokines” 1989, Fundamental Immunology, 2d ed., Raven Press, N.Y., pp. 621-638.
Gottesman & Pastan., “Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter”Annu. Rev. Biochem,62:385 (1993).
Gros et al., “Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells”Proc. Natl. Acad. Sci.USA 83:337 (1986).
Gupta et al., “P-Glycoprotein (MDR 1 Gene Product) in Cells of the Immune System: Its Possible Physiologic Role and Alteration in Aging and Human Immunodeficiency Virus-1 (HIV-1) Infection”J. Clin. Immunol.13:289 (1990).
Hamada et al., “Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies”PNAS83:7785-7789 (1986).
Hamada et al., “Mouse-Human Chimeric Antibody against the Multidrug Transporter P-Glycoprotein” 1990,Cancer Res.50:3167.
Heike et al., “Monoclonal Anti-P-glycoprotein Antibody-dependant Killing of Multidrug-Resistant Tumor Cells by Human Mononuclear Cells”Jpn. J. Cancer Res.81:1155-61 (1990).
Higgins, “ABC Transporters: from Microorganisms to Man”Annu. Rev. Cell Biol.8:67 (1992).
Hoogenboom et al., “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains”Nucleic Acids Research19(15):4133-4137, Aug. 11, 1991.
Takeda et al., “Analysis and in vivo disruption of the gene coding for calmodulin inSchizosaccharaomyces pombe” Proc. Natl. Acad. Sci.USA 84:3580 (1988).
Klimecki et al., “P-Glycoprotein Expression and Function in Circulating Blood Cells from Normal volunteers”Blood83:2451 (1994).
Kobayashi et al., “Expression and Function of Multidrug Resistance P-Glycoprotein in a Cultured Natural Killer Cell-Rich Population Revealed by Mrk16 Monoclonal Antibody and AHC-52”Biochem. Pharmacol.48:1641 (1994).
Kronke et al., “Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription”Proc. Natl. Sci. USA81:5214-5218 (1984).
Kramer et al., “The gapped duplex DNA approach to oligonucleotide-directed mutation construction”Nucleic Acids Res.12:9441-9456 (1984).
Kuwazuru et al., “Expression of the Multidrug Transporter, P-Glycoprotein, in Acute Leukemia Cells and Correlation to Clinical Drug Reistance”Cancer66(5):868 (1990).
Lazar et al., “Transforming Growth Factor α: Mutation of Asparte Acid 47 and Leucine 48 Results In Different Biological Activities”Molecular and Cellular Biology8(3):1247-1252 (1988).
Lokhorst et al., “Advances in the treatment of multiple myeloma” Cancet Treatment Reviews 19:113-128 (1993).
Maino et al., “Rapid Flow Cytometric Method for Measuring Lymphocyte Subset Activation”Cytometry20: 127-133 (1995).
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains” Nature 348:552-554 (1990).
McDuffie et al., “Morbidity Impact of Rheumatoid Arthritis on Society”Am. J. Med.78(1A): 1-5 (Jan. 21, 1985).
McGrath, “The yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-glycoprotein” Nature 340:400 (1989).
Mechetner et al., “Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody&#x
Fruehauf John
Mechetner Eugene
Harris Alana M.
McDonell Boehnen Hulbert & Berghoff
Oncotech, Inc.
LandOfFree
Methods and reagents for preparing and using immunological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for preparing and using immunological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for preparing and using immunological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3663874